Supply Chain Disruption Fuels Unexpected Optimism for Evonik

Barclays upgrades Evonik to Overweight, citing tight methionine supply and hidden value in Syneqt unit sale. Dividend to be cut temporarily from 2025.

While geopolitical tensions and worldwide supply bottlenecks are crippling numerous industrial firms, Essen-based specialty chemicals group Evonik is experiencing a surprising positive reversal. Market experts at a major British bank have reassessed the company's equity, identifying significant upside potential driven by unforeseen market dynamics, even as the share price exhibits near-term softness.

Analyst Upgrade and Revised Price Target

Barclays Investment Bank has revised its rating on Evonik from 'Equal Weight' to 'Overweight', simultaneously lifting its price target from 16 to 17 euros. This reassessment is primarily linked to the global market for methionine, a key amino acid used in animal feed. Contrary to earlier analyst expectations of a price decline, logistical disruptions stemming from the Middle East conflict are now constricting supply.

Evonik was compelled to declare force majeure at its Singapore production facility due to a shortage of critical precursor materials. This global supply tightness is providing substantial support to selling prices, transforming what was once a margin risk for the company into a profitable earnings driver. Barclays also notes that Evonik is structurally less vulnerable to high gas prices than many industry peers, as management proactively secured lower energy costs for 2026.

Strategic Restructuring and Hidden Value

The ongoing corporate restructuring presents another potential catalyst for the stock's valuation. Debt reduction and portfolio optimization are central pillars of the company's strategy through 2027. In particular, the potential divestment of the infrastructure unit, Syneqt, is coming into focus. This division contributes an operating result (EBITDA) of approximately 200 million euros and could command a valuation in a sale significantly above the current group average.

From an operational standpoint, management continues to provide stable guidance. Adjusted EBITDA for 2025 met expectations at 1.87 billion euros. For 2026, the company is targeting a range of 1.7 to 2.0 billion euros, aligning with prevailing analyst forecasts.

Solid Outlook Contrasts with Dividend Adjustment

Shareholders, however, must prepare for a reduced payout. For 2025, the dividend will be temporarily lowered from 1.17 euros to 1.00 euros per share. Starting in 2026, a new policy will take effect, targeting a payout ratio of 40 to 60 percent of net income.

Despite the positive analyst commentary and solid annual figures, investor reaction on Friday remained cautious. The share price currently trades at 14.00 euros, marking a slight daily decline of 0.92 percent. This leaves the stock trading well below its 52-week high of 21.52 euros.

The upcoming Annual General Meeting on June 3, 2026, will formally ratify the new dividend policy. Until then, a technical recovery in the share price is largely contingent on management demonstrating concrete progress on the sale of the Syneqt division and successfully defending current price levels in the methionine business over the coming quarters.